nuclear-news

The NEJM report concludes that “men treated by self-referring urologists, as compared with men treated by non-self-referring urologists, are much more likely to undergo IMRT, a treatment with a high reimbursement rate, rather than less expensive options, despite evidence that all treatments yield similar outcomes.”

At a press conference unveiling the study tomorrow, one of the nation’s leading urologists, James L. Mohler, MD, of Roswell Park Cancer Institute in Buffalo, will release a joint statement on the overtreatment of prostate cancer and physician self-referral from the expert members of the NCCN® Prostate Cancer Guidelines Panel, which he chairs.

“We are concerned unanimously by the prostate cancer treatment patterns identified in today’s article,” says Dr. Mohler. “We are disappointed to learn that urologists who self-refer for IMRT services use this expensive technology more than urologists who don’t self-refer and more than NCCN® Member Institutions.” He added, “Prostate cancer treatment recommendations should be based on the best available clinical evidence and not influenced by business or personal interests of the care provider.”……

The NEJM report concludes that “men treated by self-referring urologists, as compared with men treated by non-self-referring urologists, are much more likely to undergo IMRT, a treatment with a high reimbursement rate, rather than less expensive options, despite evidence that all treatments yield similar outcomes.”

At a press conference unveiling the study tomorrow, one of the nation’s leading urologists, James L. Mohler, MD, of Roswell Park Cancer Institute in Buffalo, will release a joint statement on the overtreatment of prostate cancer and physician self-referral from the expert members of the NCCN® Prostate Cancer Guidelines Panel, which he chairs.

“We are concerned unanimously by the prostate cancer treatment patterns identified in today’s article,” says Dr. Mohler. “We are disappointed to learn that urologists who self-refer for IMRT services use this expensive technology more than urologists who don’t self-refer and more than NCCN® Member Institutions.” He added, “Prostate cancer treatment recommendations should be based on the best available clinical evidence and not influenced by business or personal interests of the care provider.”……http://www.sciencedaily.com/releases/2013/10/131024101909.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fscience_society%2Feconomics+(ScienceDaily%3A+Science+%26+Society+News+–+Economics)